• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Pimavanserin continuation lower psychosis relapse risk in patient with dementia-related psychosis

byHarsh Shah
October 7, 2021
in Chronic Disease, Neurology, Psychiatry
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Pimavanserin was shown to lead to a lower risk of relapse of psychosis in patients who had an initial response to pimavanserin for dementia-related psychosis.  

2. The trial was stopped early for efficacy.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Dementia-related psychosis results in behavioral disturbances, decreased quality of life, and more rapid cognitive decline. Typical and atypical antipsychotics have been used to manage the psychosis symptoms; however, side effects such as worsening parkinsonism, extrapyramidal side effects, and metabolic abnormalities minimize their use. Pimavanserin, a serotonin-receptor modulator, has been effective in reducing psychotic symptoms in patients with Alzheimer’s disease. As such, this study determined the safety and efficacy of pimavanserin in the treatment of delusions and hallucinations associated with common forms of dementia. The study was designed as a discontinuation trial to determine whether pimavanserin treatment could confer sustained benefits. The study determined pimavanserin led to a lower risk of relapse in patients with an initial response to the therapy. Additionally, adverse effects attributed to pimavanserin included urinary tract infection, asymptomatic QT prolongation, and headache. The randomized control trial was limited by a short study period since the study was stopped early due to efficacy. Nonetheless, this study’s results are significant, and its findings highlight an alternative medication that can be used to treat psychotic symptoms in patients with dementia.

Click to read the study in NEJM

Relevant Reading: Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo controlled phase 3 trial

In-Depth [randomized controlled trial]: This randomized control trial study enrolled 392 participants across 101 clinical sites in North America, Europe, and South America. Participants included in the study were between 50 to 90 years of age and met clinical criteria for at least one of the following: Parkinson’s disease dementia, dementia with Lewy bodies, Alzheimer’s disease, frontotemporal dementia, or vascular dementia. Participants who received antipsychotics within two weeks of enrollment were excluded from this study. For the double-blind phase study, the participants were randomized in a 1:1 ratio to receive pimavanserin or placebo, respectively for 26 weeks. The primary endpoint was the time from randomization to relapse. The frequency of relapse was 13% in the pimavanserin group compared to 28% in the control group (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.17 to 0.73; P = 0.005). Since the significance level for the Cox regression analysis was below 0.0066 – the prespecified stopping boundary – the study was stopped. Between the open-label phase and double-blind phase studies, a total of five participants had a prolonged QT interval as an adverse event (open-label phase, 0.5% [2 participants]; double-blind trial, 2.9% [3 participants]). Taken together, discontinuation of pimavanserin led to a higher rate of relapse than continuing the treatment in patients for psychosis related to several types of neurodegenerative disease.

RELATED REPORTS

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Rare APOE missense variants V236E and R251G associated with substantial reduction in risk of Alzheimer disease

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Alzheimer’s diseasedementiadementia with Lewy bodiesfrontotemporal dementiaParkinson DiseasePimavanserinPsychosisvascular dementia
Previous Post

Two-year anastrozole treatment beneficial for disease-free survival in postmenopausal breast cancer

Next Post

#VisualAbstract: Dose-escalated intensity-modulated radiotherapy does not improve survival for patients with laryngeal or hypopharyngeal cancers

RelatedReports

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial
StudyGraphics

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 29, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 17, 2022
Amyloid pathology may be detected decades prior to Alzheimer’s diagnosis
Chronic Disease

Rare APOE missense variants V236E and R251G associated with substantial reduction in risk of Alzheimer disease

June 2, 2022
Chronic Disease

Decline in gait speed paired with domain-specific cognition decline may be a useful screening assessment for dementia

May 31, 2022
Next Post
#VisualAbstract: Extended letrozole therapy improves disease-free survival in postmenopausal patients with breast cancer

#VisualAbstract: Dose-escalated intensity-modulated radiotherapy does not improve survival for patients with laryngeal or hypopharyngeal cancers

#VisualAbstract Persistent chemotherapy-induced alopecia was more severe with the use of taxanes in breast cancer survivors

#VisualAbstract Persistent chemotherapy-induced alopecia was more severe with the use of taxanes in breast cancer survivors

2 Minute Medicine Rewind May 20, 2019

Active search for pulmonary embolism does not change outcomes in patients with chronic obstructive pulmonary disease exacerbation

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
  • FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.